title: Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma.
abstract: Several studies have demonstrated that oncogenic BRAF(V600E)promotes T-cell suppression in melanoma by upregulating the transcription of a multitude of immunomodulatory chemokine and cytokine genes. BRAF(V600E)has now been shown to act even more directly to evade cytotoxic T-cell recognition, by driving rapid internalization of human leukocyte antigen (HLA) class I from the tumor-cell surface and its intracellular sequestration.
authors.affiliation: Department of Melanoma Medical Oncology and Department of Immunology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
authors.forename: Sherille D
authors.initials: SD
authors.lastname: Bradley
authors.affiliation: Department of Melanoma Medical Oncology and Department of Immunology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
authors.forename: Brenda
authors.initials: B
authors.lastname: Melendez
authors.affiliation: Department of Melanoma Medical Oncology and Department of Immunology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
authors.forename: Amjad
authors.initials: A
authors.lastname: Talukder
authors.affiliation: Department of Melanoma Medical Oncology and Department of Immunology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
authors.forename: Gregory
authors.initials: G
authors.lastname: Lizée
keywords: BRAF V600E; Cancer; Cytotoxic T cell; HLA; MHC class I; immune suppression; immunotherapy; interleukin-1; melanoma; oncogene; oncogene targeted therapies